Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women

Stefano Palomba, Annalidia Sammartino, Costantino Di Carlo, Pietro Affinito, Fulvio Zullo, Carmine Nappi

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate the effects of raloxifene administration on uterine and uterine leiomyoma sizes in postmenopausal women. Design: Prospective randomized, double-blind, placebo-controlled clinical trial. Setting: Department of Gynecology, Obstetrics, and Pathophysiology of Human Reproduction, University of Naples 'Federico II', Italy. Patient(s): Seventy spontaneous postmenopausal women affected by uterine leiomyomas.Intervention(s): Twelve cycles (of 28 days each) of treatment with raloxifene (60 mg daily per os) or placebo. Main Outcome Measure(s): At entry and at every 3 cycles, uterine and uterine leiomyoma dimensions were measured by means of transvaginal ultrasound. The difference between uterine and leiomyoma volumes (Δ size) was calculated in all subjects. The characteristics of uterine bleeding and the side effects of the treatments were assessed using a daily diary. Result(s): After 6, 9, and 12 cycles of therapy, in subjects treated with raloxifene, the mean uterine and uterine leiomyoma size were significantly decreased, and the mean Δ size significantly increased in comparison with basal values and the placebo group. No significant differences in uterine bleeding were detected between the two groups. Conclusion(s): In postmenopausal women raloxifene appears to act selectively on uterine leiomyomas, reducing their size.

Original languageEnglish
Pages (from-to)38-43
Number of pages6
JournalFertility and Sterility
Volume76
Issue number1
DOIs
Publication statusPublished - 2001

Fingerprint

Leiomyoma
Uterine Hemorrhage
Placebos
Therapeutics
Hospital Obstetrics and Gynecology Department
Controlled Clinical Trials
Gynecology
Italy
Reproduction
Raloxifene Hydrochloride
Outcome Assessment (Health Care)

Keywords

  • Hormone replacement therapy
  • Leiomyoma
  • Postmenopause
  • Raloxifene
  • Sex hormone

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Palomba, S., Sammartino, A., Di Carlo, C., Affinito, P., Zullo, F., & Nappi, C. (2001). Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertility and Sterility, 76(1), 38-43. https://doi.org/10.1016/S0015-0282(01)01849-0

Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. / Palomba, Stefano; Sammartino, Annalidia; Di Carlo, Costantino; Affinito, Pietro; Zullo, Fulvio; Nappi, Carmine.

In: Fertility and Sterility, Vol. 76, No. 1, 2001, p. 38-43.

Research output: Contribution to journalArticle

Palomba, S, Sammartino, A, Di Carlo, C, Affinito, P, Zullo, F & Nappi, C 2001, 'Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women', Fertility and Sterility, vol. 76, no. 1, pp. 38-43. https://doi.org/10.1016/S0015-0282(01)01849-0
Palomba, Stefano ; Sammartino, Annalidia ; Di Carlo, Costantino ; Affinito, Pietro ; Zullo, Fulvio ; Nappi, Carmine. / Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. In: Fertility and Sterility. 2001 ; Vol. 76, No. 1. pp. 38-43.
@article{8efeca3013724c959c5219a9a2c705a4,
title = "Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women",
abstract = "Objective: To evaluate the effects of raloxifene administration on uterine and uterine leiomyoma sizes in postmenopausal women. Design: Prospective randomized, double-blind, placebo-controlled clinical trial. Setting: Department of Gynecology, Obstetrics, and Pathophysiology of Human Reproduction, University of Naples 'Federico II', Italy. Patient(s): Seventy spontaneous postmenopausal women affected by uterine leiomyomas.Intervention(s): Twelve cycles (of 28 days each) of treatment with raloxifene (60 mg daily per os) or placebo. Main Outcome Measure(s): At entry and at every 3 cycles, uterine and uterine leiomyoma dimensions were measured by means of transvaginal ultrasound. The difference between uterine and leiomyoma volumes (Δ size) was calculated in all subjects. The characteristics of uterine bleeding and the side effects of the treatments were assessed using a daily diary. Result(s): After 6, 9, and 12 cycles of therapy, in subjects treated with raloxifene, the mean uterine and uterine leiomyoma size were significantly decreased, and the mean Δ size significantly increased in comparison with basal values and the placebo group. No significant differences in uterine bleeding were detected between the two groups. Conclusion(s): In postmenopausal women raloxifene appears to act selectively on uterine leiomyomas, reducing their size.",
keywords = "Hormone replacement therapy, Leiomyoma, Postmenopause, Raloxifene, Sex hormone",
author = "Stefano Palomba and Annalidia Sammartino and {Di Carlo}, Costantino and Pietro Affinito and Fulvio Zullo and Carmine Nappi",
year = "2001",
doi = "10.1016/S0015-0282(01)01849-0",
language = "English",
volume = "76",
pages = "38--43",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women

AU - Palomba, Stefano

AU - Sammartino, Annalidia

AU - Di Carlo, Costantino

AU - Affinito, Pietro

AU - Zullo, Fulvio

AU - Nappi, Carmine

PY - 2001

Y1 - 2001

N2 - Objective: To evaluate the effects of raloxifene administration on uterine and uterine leiomyoma sizes in postmenopausal women. Design: Prospective randomized, double-blind, placebo-controlled clinical trial. Setting: Department of Gynecology, Obstetrics, and Pathophysiology of Human Reproduction, University of Naples 'Federico II', Italy. Patient(s): Seventy spontaneous postmenopausal women affected by uterine leiomyomas.Intervention(s): Twelve cycles (of 28 days each) of treatment with raloxifene (60 mg daily per os) or placebo. Main Outcome Measure(s): At entry and at every 3 cycles, uterine and uterine leiomyoma dimensions were measured by means of transvaginal ultrasound. The difference between uterine and leiomyoma volumes (Δ size) was calculated in all subjects. The characteristics of uterine bleeding and the side effects of the treatments were assessed using a daily diary. Result(s): After 6, 9, and 12 cycles of therapy, in subjects treated with raloxifene, the mean uterine and uterine leiomyoma size were significantly decreased, and the mean Δ size significantly increased in comparison with basal values and the placebo group. No significant differences in uterine bleeding were detected between the two groups. Conclusion(s): In postmenopausal women raloxifene appears to act selectively on uterine leiomyomas, reducing their size.

AB - Objective: To evaluate the effects of raloxifene administration on uterine and uterine leiomyoma sizes in postmenopausal women. Design: Prospective randomized, double-blind, placebo-controlled clinical trial. Setting: Department of Gynecology, Obstetrics, and Pathophysiology of Human Reproduction, University of Naples 'Federico II', Italy. Patient(s): Seventy spontaneous postmenopausal women affected by uterine leiomyomas.Intervention(s): Twelve cycles (of 28 days each) of treatment with raloxifene (60 mg daily per os) or placebo. Main Outcome Measure(s): At entry and at every 3 cycles, uterine and uterine leiomyoma dimensions were measured by means of transvaginal ultrasound. The difference between uterine and leiomyoma volumes (Δ size) was calculated in all subjects. The characteristics of uterine bleeding and the side effects of the treatments were assessed using a daily diary. Result(s): After 6, 9, and 12 cycles of therapy, in subjects treated with raloxifene, the mean uterine and uterine leiomyoma size were significantly decreased, and the mean Δ size significantly increased in comparison with basal values and the placebo group. No significant differences in uterine bleeding were detected between the two groups. Conclusion(s): In postmenopausal women raloxifene appears to act selectively on uterine leiomyomas, reducing their size.

KW - Hormone replacement therapy

KW - Leiomyoma

KW - Postmenopause

KW - Raloxifene

KW - Sex hormone

UR - http://www.scopus.com/inward/record.url?scp=0034960808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034960808&partnerID=8YFLogxK

U2 - 10.1016/S0015-0282(01)01849-0

DO - 10.1016/S0015-0282(01)01849-0

M3 - Article

C2 - 11438317

AN - SCOPUS:0034960808

VL - 76

SP - 38

EP - 43

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 1

ER -